A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Or Metastatic Solid Tumors
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Phase 1: Subjects with advanced or metastatic HNSCC, NSCLC, ovarian, PD-L1 low (TPS <50%) expressing malignancies, cervical cancer, endometrial cancer, gastric cancer (including stomach, esophageal, and gastroesophageal junction), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) colorectal cancer (CRC), renal cell carcinoma (RCC), triple negative breast cancer (TNBC), and urothelial carcinoma. 2) Phase 2: Subjects with advanced or metastatic HNSCC, NSCLC, ovarian, and PD-L1 low (TPS <50%) expressing malignancies.

You may not be eligible for this study if the following are true:

  • 1) Has not recovered to = Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy. 2) Receipt of a live vaccine within 30 days of planned start of study therapy. 3) Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Subjects who have not required systemic treatment in the past 2 years may be eligible with approval of the medical monitor.
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.